SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Claris Lifesciences receives PAS for Furosemide Injection in US

12 Aug 2015 Evaluate

Claris Lifesciences has received the Prior Approval Supplement (PAS) for Furosemide Injection in the United States of America (US). The company had received the original approval for this ANDA in January 2014 and was selling the products in the US in 2014. But, since January 2015, the company has been facing supply issues from its raw material supplier and has not been able to supply its product to the US.

The company had filed a PAS application to append an additional supplier to the ANDA, this process was done for redundancy and to ensure a consistent supply of the API for its finished formulation sold in the US. With this approval, alterative vendor has been appended to the ANDA this will allow the company to recommence its supplies to the US. The product had been facing supply issues in USA during the past year on various occasions and has also featured in the USFDA shortage list since June 2012.

Claris is also one of the few injectables companies in India to have its own front end in the US, the company markets its products through its wholly owned subsidiary Claris Lifesciences Inc. The company has 13 ANDAs approved in its name across 8 molecules. The company has a under registration pipeline of 24 ANDAs across 21 molecules having an estimated addressable market size of $2.2 billion.


Peers
Company Name CMP
Redington 227.50
Adani Enterprises 2228.00
Amrapali Industries 17.36
Rashi Peripheral 474.40
PDS 294.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×